enGene to Participate in Upcoming Investor Conferences

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage genetic medicines company whose non-viral lead program detalimogene voraplasmid (also known as detalimogene, and previously EG-70), is in an ongoing pivotal study in patients with high-risk, Bacillus Calmette-Guérin (BCG)-unresponsive, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis), today announced that the Company will participate in several upcoming investor conferenced scheduled to take place in September 2024.

Details of the conferences are below:

Conference: Morgan Stanley 22nd Annual Healthcare Conference
Date: Thursday, September 5, 2024
Time: 4:50 p.m. ET
Location: New York, NY
Format: Fireside Chat
Presenters: Ron Cooper, Chief Executive Officer; Raj Pruthi, Chief Medical Officer

Conference: Wells Fargo Healthcare Conference
Date: Friday, September 6, 2024
Time: 11:00 a.m. ET
Location: Everett, MA
Format: Corporate Presentation
Presenter: Ron Cooper, Chief Executive Officer

Conference: H.C. Wainwright 26^th Annual Global Investment Conference
Date: Wednesday, September 11, 2024
Time: 9:30 a.m. ET
Location: New York, NY
Format: Corporate Presentation
Presenter: Alex Nichols, Chief Operating Officer

A live webcast of each of these presentations can be accessed under the Investors section of the enGene website at https://engene.com/presentations/ and will be archived there for 90 days.

About enGene

enGene is a clinical-stage biotechnology company mainstreaming genetic medicines through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs. enGene’s lead program is detalimogene voraplasmid (previously known as EG-70) for patients with non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (Cis) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG) – a disease with a high clinical burden. Detalimogene voraplasmid is being evaluated in an ongoing Phase 2 pivotal study. Detalimogene voraplasmid was developed using enGene’s proprietary Dually Derivatized Oligochitosan (DDX) platform, which enables penetration of mucosal tissues and delivery of a wide range of sizes and types of cargo, including DNA and various forms of RNA. For more information, visit enGene.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240828277262/en/

Investor Contact

investors@engene.com

Media Contact

media@engene.com

Source: enGene Holdings Inc.